20250154278. Optimized Antibodies (JANUX THERAPEUTICS, INC.)
OPTIMIZED ANTIBODIES TARGETING TROP2 AND USES THEREOF
Abstract: disclosed herein are recombinant antibodies or antigen binding fragments thereof that comprise a tumor-associated calcium signal transducer 2 (trop2) binding domain that has been optimized for binding and kinetic properties. in some embodiments, the recombinant antibodies or antigen binding fragments thereof further comprise a cd3 binding domain.
Inventor(s): David CAMPBELL, Thomas R. DIRAIMONDO
CPC Classification: C07K16/30 (PEPTIDES (peptides in foodstuffs ; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs ; preparations for medicinal purposes ; peptides containing beta-lactam rings ; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, ; ergot alkaloids of the cyclic peptide type ; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids ; macromolecular products derived from proteins ; preparation of glue or gelatine ; single cell proteins, enzymes ; genetic engineering processes for obtaining peptides ; compositions for measuring or testing processes involving enzymes ; investigation or analysis of biological material ))
Search for rejections for patent application number 20250154278